CareDx, Inc (CDNA)

15.63

+0.13

(+0.84%)

At close: 4:00 PM EDT

15.89

+0.26

(+1.66%)

After hours: 4:39 PM EDT

Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

BRISBANE, Calif., May 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.

Business Wire 4 days ago

CDNA
+0.84%
Earnings Update: Here's Why Analysts Just Lifted Their CareDx, Inc (NASDAQ:CDNA) Price Target To US$13.80

As you might know, CareDx, Inc ( NASDAQ:CDNA ) just kicked off its latest quarterly results with some very strong...

Simply Wall St. 9 days ago

CDNA
+0.84%
CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance

Despite a Quarterly Revenue Decline, CareDx Optimistic About 2024 Prospects

GuruFocus.com 10 days ago

CDNA
+0.84%
CareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call Transcript May 9, 2024 CareDx, Inc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to today’s CareDx, Inc. First Quarter 2024 Earnings Conference Call. At this time, all […]

Insider Monkey 10 days ago

CDNA
+0.84%
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 10 days ago

CDNA
+0.84%
CareDx Reports First Quarter 2024 Results

BRISBANE, Calif., May 09, 2024--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024.

Business Wire 11 days ago

CDNA
+0.84%
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks 13 days ago

CDNA
+0.84%
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of common

Business Wire 17 days ago

CDNA
+0.84%
CareDx to Report First Quarter 2024 Financial Results

BRISBANE, Calif., April 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Business Wire 21 days ago

CDNA
+0.84%
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 19, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the "Inducement Option") and 487,804 restricted stock units (the "Inducement RSUs" ) to Jo

Business Wire last month

CDNA
+0.84%
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

CDNA
+0.84%
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.

Business Wire last month

CDNA
+0.84%
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif., April 09, 2024--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th An

Business Wire last month

CDNA
+0.84%
How CareDx (CDNA) Stock Stands Out in a Strong Industry

CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks last month

CDNA
+0.84%
CareDx Appoints Bryan Riggsbee to Its Board of Directors

BRISBANE, Calif., March 11, 2024--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.

Business Wire 2 months ago

CDNA
+0.84%
CareDx Full Year 2023 Earnings: EPS Misses Expectations

CareDx ( NASDAQ:CDNA ) Full Year 2023 Results Key Financial Results Revenue: US$280.3m (down 13% from FY 2022). Net...

Simply Wall St. 2 months ago

CDNA
+0.84%
CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript February 28, 2024 CareDx, Inc beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.24. CDNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to CareDx, Inc. Fourth Quarter […]

Insider Monkey 2 months ago

CDNA
+0.84%
Q4 2023 CareDx Inc Earnings Call

Q4 2023 CareDx Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CDNA
+0.84%
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

CDNA
+0.84%
CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023

Full Year Revenue Exceeds Guidance; Patent Litigation Impacts Net Loss

GuruFocus.com 2 months ago

CDNA
+0.84%

Performance Overview

Return	CDNA	S&P 500
YTD	+30.25%	+11.29%
1-Year	+103.52%	+26.63%
3-Year	-78.14%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CareDx, Inc (CDNA)

Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

Earnings Update: Here's Why Analysts Just Lifted Their CareDx, Inc (NASDAQ:CDNA) Price Target To US$13.80

CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance

CareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call Transcript

CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

CareDx Reports First Quarter 2024 Results

CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CareDx to Report First Quarter 2024 Financial Results

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?

CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

How CareDx (CDNA) Stock Stands Out in a Strong Industry

CareDx Appoints Bryan Riggsbee to Its Board of Directors

CareDx Full Year 2023 Earnings: EPS Misses Expectations

CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript

Q4 2023 CareDx Inc Earnings Call

CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023

Performance Overview